Home > Boards > US Listed > Biotechs > RedHill Biopharma Ltd. (RDHL)

Loving every minute of it!

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
DorseyE Member Profile
 
Followed By 8
Posts 2,084
Boards Moderated 0
Alias Born 08/09/03
160x600 placeholder
RedHill Biopharma Expands U.S.-Based Manufacturing Capacity of Opaganib for COVID-19 PR Newswire (US) - 11/25/2020 12:39:00 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/25/2020 10:44:03 AM
RedHill Biopharma Expands U.S.-Based Manufacturing Capacity of Opaganib for COVID-19 PR Newswire (US) - 11/25/2020 10:36:00 AM
RedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences PR Newswire (US) - 11/23/2020 9:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/23/2020 8:00:43 AM
RedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences PR Newswire (US) - 11/23/2020 8:00:00 AM
RedHill Biopharma Initiates Phase 3 Study of RHB-204 for First-Line Treatment of NTM Disease PR Newswire (US) - 11/20/2020 8:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/19/2020 7:01:07 AM
RedHill Announces Unanimous DSMB Recommendation to Continue Phase 2/3 COVID-19 Study with Opaganib PR Newswire (US) - 11/19/2020 7:00:00 AM
RedHill Biopharma's Second COVID-19 Candidate, RHB-107, Cleared by FDA for Phase 2/3 Study in Symptomatic COVID-19 Disease PR Newswire (US) - 11/17/2020 8:21:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/17/2020 7:01:08 AM
RedHill Biopharma's Second COVID-19 Candidate, RHB-107, Cleared by FDA for Phase 2/3 Study in Symptomatic COVID-19 Disease PR Newswire (US) - 11/17/2020 7:00:00 AM
RedHill Biopharma Completes Enrollment for COVID-19 U.S. Phase 2 Study with Opaganib - Data Expected in the Coming Weeks PR Newswire (US) - 11/16/2020 11:28:00 AM
RedHill Biopharma Completes Enrollment for COVID-19 U.S. Phase 2 Study with Opaganib - Data Expected in the Coming Weeks PR Newswire (US) - 11/16/2020 10:13:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/16/2020 10:01:06 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/13/2020 7:00:54 AM
RedHill Biopharma to Present at German Equity Forum 2020 GlobeNewswire Inc. - 11/13/2020 7:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/12/2020 7:01:04 AM
RedHill Biopharma Provides Q3/2020 Results and Highlights, Including 300% Talicia Prescription Growth GlobeNewswire Inc. - 11/12/2020 7:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/5/2020 7:01:02 AM
RedHill Biopharma to Host Third Quarter Financial Results and Business Highlights Webcast on November 12, 2020 GlobeNewswire Inc. - 11/5/2020 7:00:00 AM
RedHill Biopharma Receives U.S. Patent Allowance Covering Opaganib and RHB-107 Combination GlobeNewswire Inc. - 11/4/2020 10:30:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 10/26/2020 10:00:43 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 10/26/2020 9:00:57 AM
RedHill Biopharma Presents New Data from Talicia®’s Phase 3 Studies at ACG 2020 Focused on Achieving Successful First-Line... GlobeNewswire Inc. - 10/26/2020 9:00:10 AM
DorseyE   Friday, 07/31/20 12:28:23 PM
Re: midastouch017 post# 2140
Post # of 2504 
Loving every minute of it!

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences